Alhemo (Concizumab-Mtci) for Haemophilia

Overview
Alhemo is approved by the U.S. Food and Drug Administration (FDA) for the routine prophylaxis (prevention) of bleeding episodes in adults and children aged 12 years and older with hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors or hemophilia B (congenital factor IX deficiency) with FIX inhibitors. This treatment is designed to prevent or reduce the frequency of bleeding episodes. Alhemo is also known by its drug name, concizumab-mtci.

Alhemo belongs to a class of drugs called tissue factor pathway inhibitor (TFPI) antagonists. It works by targeting and inhibiting TFPI, a protein that limits blood clot formation, thereby improving clotting function in individuals with hemophilia.

How do I take it?
Prescribing information states that Alhemo is administered as a subcutaneous injection into the abdomen or thigh, with daily rotation of injection sites. Treatment begins with a one-time loading dose on the first day, followed by a once-daily maintenance dose. Four weeks after starting treatment, plasma levels of concizumab-mtci may be measured to individualize the maintenance dose. The dosing schedule should be followed precisely, and Alhemo should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Alhemo include injection site reactions and urticaria (hives).

Rare but serious side effects may include thromboembolic events (blood clots), severe hypersensitivity reactions, and increased laboratory values of fibrin D dimer and prothrombin fragment 1+2, which may indicate clotting abnormalities. 

For more information about this treatment, visit:

Alhemo (Concizumab-Mtci) Injection, for Subcutaneous Use — Novo Nordisk

Alhemo — Drugs.com